Page last updated: 2024-08-21

2-phenylbenzothiazole and Huntington Disease

2-phenylbenzothiazole has been researched along with Huntington Disease in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ayton, S; Bush, AI; Cherny, RA; Finkelstein, DI; Massa, SM; McColl, G1
Langbehn, DR1

Trials

1 trial(s) available for 2-phenylbenzothiazole and Huntington Disease

ArticleYear
Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial.
    The Lancet. Neurology, 2015, Volume: 14, Issue:1

    Topics: Adult; Biomarkers; Clioquinol; Cognition Disorders; Double-Blind Method; Female; Humans; Huntington Disease; Male; Middle Aged; Placebos; Treatment Outcome

2015

Other Studies

2 other study(ies) available for 2-phenylbenzothiazole and Huntington Disease

ArticleYear
PBT2 Reduces Toxicity in a C. elegans Model of polyQ Aggregation and Extends Lifespan, Reduces Striatal Atrophy and Improves Motor Performance in the R6/2 Mouse Model of Huntington's Disease.
    Journal of Huntington's disease, 2012, Volume: 1, Issue:2

    Topics: Animals; Atrophy; Caenorhabditis elegans; Clioquinol; Corpus Striatum; Disease Susceptibility; Dose-Response Relationship, Drug; Drug Resistance; Huntington Disease; Longevity; Mice; Mice, Transgenic; Motor Skills; Species Specificity

2012
Criteria for success in safety and tolerability trials.
    The Lancet. Neurology, 2015, Volume: 14, Issue:1

    Topics: Clioquinol; Cognition Disorders; Female; Humans; Huntington Disease; Male

2015